Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or at risk for HBV reactivation.
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration; patients who have completed curative therapy for HCV are eligible; patients with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following  criteria:\r\n* CD counts >=  mm^\r\n* Serum HIV viral load of < , IU/ml and\r\n* Treated on a stable antiretroviral regimen
Patients with known active infections with human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B (HBV), and hepatitis C virus (HCV) infections will not be considered for this trial; HIV+ patients on combination antiretroviral therapy are ineligible; testing for HIV or hepatitis is not required
Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening
Active hepatitis B virus (HBV) infection
Active hepatitis B virus (HBV) or hepatitis C (HCV) infection;
Patients with active Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immune deficiency virus (HIV) infection
Subject with known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or is known to be a carrier of hepatitis B or C.
Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; similarly, patients with chronic or acute hepatitis C virus (HCV) or hepatitis B virus (HBV) infection are also ineligible; prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin =< ULN) is allowed
Patients who have a clinically active hepatitis B or C virus infection are not eligible; NOTE: those with documented evidence of past exposure to hepatitis B virus (HBV) or hepatitis C virus (HCV) may enroll so long as the respective viral load is negative AND subject is willing/able to take appropriate antiviral prophylaxis to prevent reactivation
Is test positive for hepatitis C virus (HCV), hepatitis B virus (HBV) or human immunodeficiency virus (HIV) antibody.
Immunocompromised patients (other than that related to the use of corticosteroids) including patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Active hepatitis C virus (HCV) infection
Known history of human immunodeficiency virus (HIV), active infection with hepatitis B virus (HBV), and/or hepatitis C virus (HCV)
Known history of human immunodeficiency virus (HIV), active infection with hepatitis B virus (HBV), and/or hepatitis C virus (HCV)
Have a serious concomitant systemic disorder that would compromise the participant's ability to adhere to the protocol, including active or chronic infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment.
Human immunodeficiency virus (HIV) or hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Positive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection or active tuberculosis
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV).
Active infection with hepatitis C virus (HCV)
Active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to trial registration. Patients who have completed curative therapy for HCV are eligible. Patients with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following  criteria:\r\n* CD counts >=  mm^\r\n* Serum HIV viral load of < , IU/ml and\r\n* Treated on a stable antiretroviral regimen.
Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV); patients with HBV and/or HCV sero-positivity only will be eligible, if nucleic acid amplification testing (NAT) is negative
Patients with a history of hepatitis B virus (HBV) are excluded
Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) positive patients on antiviral drugs are excluded due to the absence of previous experience with concurrent use of antiviral medications and the investigational drug product to be evaluated in the current study and possible for adverse pharmacokinetic and/or pharmacodynamic interactions
Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).
Human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; HIV positive patients will be excluded due to a theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection
As judged by the Investigator, has any evidence of severe or uncontrolled diseases such as active bleeding diatheses, or has an active viral infection of human immunodeficiency virus (HIV), human papilloma virus (HPV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV)
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
Active hepatitis C virus (HCV) or hepatitis B virus (HBV)
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Has active co-infection with HBV and hepatitis D virus (HDV)
Patients with clinically evident human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection are excluded
Antiviral therapy for hepatitis C virus (HCV) and hepatitis B virus (HBV) is allowed, but patient should not be on interferon.
Patients known to have acute or chronic active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV).
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Patients with active hepatic disease, liver cirrhosis, or known hepatitis B virus (HBV)/hepatitis C virus (HCV) infection
Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; NOTE: HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) testing is not required
Participant is known to be positive for hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals (non-exclusionary medications) are not excluded.
DONOR: Positivity for HIV, hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]), human T-cell lymphotropic virus (HTLV-I/II)
As judged by the investigator, has any evidence of severe or uncontrolled systemic diseases such as active bleeding diatheses, is positive for human immunodeficiency virus (HIV), or has active hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
Known history of hepatitis B virus (HBV) or hepatitis C (HCV) infection
Evidence of uncontrolled viral infection including Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Human Herpes Virus- (HHV-), Hepatitis Virus (HBV), or Hepatitis C Virus (HCV) based on assessment by the treating physician.
Known seropositivity for, or active viral infection with, human immunodeficiency virus (HIV), hepatitis B virus (HBV) (unless due to vaccination), or hepatitis C virus (HCV); HIV-positive patients on combination antiretroviral therapy are ineligible
Human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection due to risk of progression while receiving immunosuppressive chemotherapy
Human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; HIV positive patients will be excluded
Have a serious concomitant systemic disorder including human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorder or disease requiring high dose of steroids.
mCRPC EXPANSION COHORT: Hepatitis B virus (HBV) -or hepatitis C virus (HCV)-positive patients are ineligible
Known active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Has a known human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infection
Patients who test positive for hepatitis B virus (HBV) or hepatitis C virus (HCV)
For non-HCC, there must not be acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
PHASE I STUDY ELIGIBILITY CRITERIA: \r\nHepatitis B virus (HBV)-or hepatitis C virus (HCV)-positive patients are ineligible
Known positive for human immunodeficiency virus (HIV); active hepatitis B (HBV) or hepatitis C (HCV) infection
Known sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligible
Human immunodeficiency virus (HIV) positive (recipients who are positive for hepatitis B [hepatitis B virus (HBV)], hepatitis C [hepatitis C virus (HCV)] or human T-cell lymphotropic virus [HTLV]-I/II are not excluded from participation)
Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed); patients with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications
Has a known human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C (HCV) infection
DONOR: Must be human immunodeficiency virus (HIV)-& antibody, HTLV-I&II antibody, hepatitis B virus (HBV) and hepatitis C virus (HCV) sero-negative, by Food and Drug Administration (FDA) licensed test
Patients with history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C\r\n* Note: patients who have a history of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are eligible, however, they must receive prophylactic antiviral therapy for - weeks prior to receiving study drug
Known sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligible
Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
Have an ongoing or active infection, including but not limited to, the requirement for intravenous (IV) antibiotics, or a known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Testing is not required in the absence of history.
Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Known history of Human Immunodeficiency Virus (HIV) or active infection with Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or any uncontrolled active systemic infection.
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Positive human immunodeficiency virus (HIV) test, active tuberculosis, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Active Epstein-Barr virus (EBV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Active hepatitis B virus (HBV) infection
Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Known hepatitis B virus (HBV) or hepatitis C virus (HBV) infection
Patients with history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) due to potentially increased risk of mithramycin toxicity in this population
Patients with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infections
Human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) seropositivity
Patient has a current active infectious disease or known positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), or hepatitis A virus (HAV)
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; patients must have negative testing for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) within  weeks prior to randomization
Patients with evidence of hepatitis C virus (HCV) or hepatitis B virus (HBV) infection must have no clinical evidence of cirrhosis
Has a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
Active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (unless cleared) will be excluded
Patient must not be known to be human immunodeficiency virus (HIV)-positive, hepatitis B-positive, or hepatitis C-positive (with the exception of chronic or cleared hepatitis B virus [HBV] or hepatitis C virus [HCV] infection, which will be allowed)
Hepatitis B virus (HBV) or untreated systemic infection
Has controlled infection by Hepatitis B Virus (HBV).
Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections or positive human immunodeficiency virus (HIV) antibody results. Patients with sustained virologic response to HCV treatment or immunity to HBV from prior infection without cirrhosis may be included.
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
Significant life-threatening extra-hepatic disease, including patients who are on dialysis, have unresolved diarrhea, have serious unresolved infections including patients who are known to be human immunodeficiency virus (HIV) positive or have acute hepatitis B virus (HBV) or hepatitis C virus (HCV)
Positive hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection at screening
Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection
Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection.
HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
Active uncontrolled infection. Active hepatitis B or C virus (HBV or HCV), or human immunodeficiency virus (HIV)infection.
Patients with known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
Known acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Has untreated active Hepatitis B virus (HBV)
Uncontrolled infectious diseases - requires negative tests for clinically suspected human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV).
Active human immunodeficiency virus (HIV), Hepatitis B Virus (HBV) or hepatitis C virus (HCV) infections at the time of screening. Subjects with laboratory evidence of HCV clearance may be enrolled.
Known severe and/or uncontrolled medical disorder that would impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease, human immunodeficiency virus [HIV], hepatitis B virus [HBV], hepatitis C virus [HCV], or active infection)
Known HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or at risk for HBV reactivation
Negative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV); if testing was done within the past three months, there is no need to repeat testing, as long as documentation of results is provided to the study site; subjects must receive counseling and sign a separate informed consent for HIV testing
Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment or have an active infection that is clinically serious in the investigator's opinion.
Human Immunodeficiency Virus (HIV), or active Hepatitis C (HCV) virus. Escalation: active Hepatitis B (HBV); Expansion: Patients with Chronic HBV currently on medication will not be excluded.
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Active infection with human immunodeficiency virus (HIV), hepatitis B Virus (HBV), or hepatitis C Virus (HCV)
Patients who test positive for hepatitis B virus (HBV) or hepatitis C virus (HCV)
Subjects who have a history of human immunodeficiency virus (HIV) infection or subjects who have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment.
Known positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
Subjects with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
Known history of human immunodeficiency virus (HIV), chronic hepatitis B virus (HBV), or active hepatitis C virus (HCV); Note: subjects with serologic evidence of prior vaccination to HBV (i.e., hepatitis B surface antigen negative [HBs Ag-], hepatitis B virus core antibody negative [anti-HBc-]) and positive anti-HBc from intravenous immunoglobulin (IVIG) may participate
Known human immunodeficiency virus (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBC and HCV infection, which will be allowed)
Known active human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)
Patient has acute viral hepatitis or a history of chronic or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Patients with clinically evident Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C virus (HCV), or Epstein-Barr virus (EBV) infection are excluded.
Known sero-positive for active or past viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligible
Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV).
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.
Is known to have human immunodeficiency virus (HIV) or has active hepatitis C virus (HCV), or active hepatitis B virus (HBV)
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.
Subjects with known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)
Positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection
Documentation on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology is required
Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Patients must not have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Subjects with known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV), because eltrombopag is hepatically cleared, and underlying hepatic impairment may lead to an increased risk of hepatotoxicity. Eltrombopag has not been evaluated with combination antiretroviral regimens.
Patients who test positive for hepatitis B virus (HBV) or hepatitis C virus (HCV)
Patients with a known history of infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Active human immunodeficiency virus  (HIV-), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection
Clinically relevant active infection including active hepatitis B or C or human immunodeficiency virus (HBV, HCV, or HIV) or any other concurrent disease
Presence of active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection, history of human immunodeficiency virus (HIV), or other uncontrolled systemic infection
Patients with a history of human immunodeficiency virus (HIV) infection; active viral infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
Known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
History of human immunodeficiency virus (HIV) or an active and uncontrolled infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)
Liver disease: Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation.
Known active hepatitis B (HBV), hepatitis C (HCV) or human immunodeficiency virus (HIV) infections; Note: pretesting is not required
Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and/or Hepatitis C Virus (HCV) infection.
Known Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV), and/or active Hepatitis C Virus (HCV) infection.
Positive hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection at screening
Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infections. Subjects with laboratory evidence of HBV clearance may be enrolled
Have a serious concomitant systemic disorder including human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active HCV, active autoimmune disorder or disease requiring high dose of steroids
Positive serology test for hepatitis B virus (HBV), hepatitis C virus (HCV), or active tuberculosis
Known history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis
Active infection requiring systemic therapy, including known human immunodeficiency virus (HIV), acquired immunodeficiency syndrome-related illness, or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Pts with known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) disease (routine testing is not needed if not clinical indicated)
Patients with known or suspected infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) or other infectious hepatitis
Ongoing or active infection including known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV); testing for these viruses is not required in the absence of a history of infection
Negative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV); if testing was performed during the previous  months, there is no need to repeat testing, as long as documentation of results is provided to the study site; subjects must receive counseling and sign a separate informed consent form for HIV testing
Negative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV) antigen, and hepatitis C virus (HCV); if testing was performed during the previous  months, there is no need to repeat testing, as long as documentation of results is provided to the study site; subjects must receive counseling and sign a separate informed consent form for HIV testing
Subjects must meet the protocol-defined criteria for both hepatitis B virus (HBV) and hepatitis C virus (HCV) status
Known sero-positive for active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are sero-positive because of hepatitis B virus vaccine are eligible
Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)-positive participants with active infection
Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients with prior exposure to hepatitis, but no evidence of active or chronic infection, may be eligible
Known infection with hepatitis B virus (HBV) and hepatitis C virus (HCV); testing may have been done up to  months prior to treatment
Known human immunodeficiency virus infection, or hepatitis B virus (HBV) viremia or hepatitis C virus (HCV) viremia; screening for the study does not require assessment for these infections if not already known; any other condition that, in the opinion of the investigator, may compromise the safety, compliance of the patient, or would preclude the patient from successful completion of the study
A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection
Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)
Concomitant diseases/conditions as unstable angina, myocardial infarction, symptomatic congestive heart failure or asymptomatic with left ventricular ejection fraction (LVEF) ? %, dyspnea, infection by human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active uncontrolled infection, pleural or pericardial effusions, myopathy, limitation of the patient's ability to comply with the treatment or to follow-up the protocol, any other major illness
Patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Patients with known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.
Current known active infection with human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C virus; for patients who are known carriers of hepatitis B virus (HBV), active hepatitis B infection must be ruled out based on negative serologic testing and/or determination of HBV deoxyribonucleic acid (DNA) viral load per local guidelines
Known history of hepatitis B virus (HBV), hepatitis C virus (HCV), or active tuberculosis. Known history of human immunodeficiency virus (HIV) type / or other immunodeficiency disease.
Patients with a history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Concomitant interferon therapy or therapies for active Hepatitis C virus (HCV) infection
A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.
Patients with active or chronic hepatitis C virus (HCV)
Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible: \r\n* Ongoing or active infection requiring systemic treatment\r\n* Symptomatic congestive heart failure (>= class )\r\n* Unstable angina pectoris\r\n* Cardiac arrhythmia\r\n* Psychiatric illness/social situations that would, in the investigators opinion, limit compliance with study requirements\r\n* Known human immunodeficiency virus (HIV) infection\r\n* Known John Cunningham virus (JC) virus infection and/or progressive multifocal leukoencephalopathy (PML)\r\n* Known clinically active hepatitis A, B, or C infections\r\n** NOTE: Patients with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection may enroll if other laboratory criteria are met; those with HBV surface antigen positivity may enroll only if maintained on appropriate suppressive antiviral therapy for the duration of enrollment in the trial\r\n* Second malignancy that requires active treatment\r\n* Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patients safety or study endpoints
Has a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
Active human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infections at the time of screening.
Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within  months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease
Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within  months of registration
Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and active hepatitis B virus (HBV) (surface antigen negative) within  months of registration
Known history of human immunodeficiency virus (HIV), chronic hepatitis B virus (HBV), or hepatitis C (HCV) requiring treatment; Note: Subjects with serologic evidence of prior vaccination to HBV (i.e., hepatitis B virus surface antigen negative [HBs Ag-], anti-HBs+ and anti-hepatitis B virus core negative[HBc-]) and positive anti-HBc from intravenous immunoglobulin (IVIG) may participate
Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests
Active/chronic human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection
Ongoing hepatitis B virus (HBV) infection
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment or at risk for HBV reactivation.
DONOR: Positive for human immunodeficiency virus (HIV), active hepatitis B (hepatitis B virus [HBV]), hepatitis C (hepatitis C virus [HCV]) or human T?cell lymphotropic virus (HTLV?I/II)
Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV); this information will be obtained verbally from the patient
Known Human Immunodeficiency Virus (HIV) or Hepatitis C (HCV) infection, or evidence of active Hepatitis B Virus (HBV) infection
Known hepatitis A virus (HAV), hepatitis B virus (HBV) or hepatitis C virus (HCV) positivity with evidence of ongoing infection.
Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).
Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligible
Patients who have a known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV)
Known human immunodeficiency virus (HIV), active Hepatitis B (HBV) or Hepatitis C (HCV) infection
Active chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active HIV, or cytomegalovirus (CMV) infection.
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
Known human immunodeficiency virus (HIV), recent hepatitis B virus (HBV), hepatitis C virus (HCV)
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
